Akura Medical has announced the closing of its $25M Series A1 financing, which will be used to support the development of its next-generation thrombectomy device.
The financing was led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), PA MedTech VC Fund and Shifamed angel investors.
Amr Salahieh, founder of Shifamed and chairman of the board of Akura Medical, said: “Akura Medical’s mechanical thrombectomy device is designed to simplify the procedure and integrate various mechanisms to efficiently and effectively remove blood clots.
“We are extremely pleased to close this oversubscribed round of financing. The strong interest from investors validates the clear unmet need in this space and we look forward to expanding our world-class team as we drive towards the next development milestones.”
Bihua Chen, founder and managing member of Cormorant Asset Management, added: “Venous thromboembolism (VTE) is a large market that is currently underserved due to limitations of existing treatment options.
“We are excited to lead this round and believe there is ample room for improvement over existing treatments. Akura Medical’s differentiated technology has the potential to overcome these shortcomings with its elegant mechanical thrombectomy solution.”
